Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 56, Issue 94-95, 2009, Pages 1417-1424

  Gadelhak, Nabil A ^a   Gadelhak, Seham A ^b   El Wahab El Morsi, Doaa A ^b   Abdelaziz, Mohamed M ^a   Abbas, Ayman T ^a   El Emshaty, Hoda M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Alpha fetoprotein; HCC; p53; VEGF

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTEIN ANTIBODY; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER PATIENT; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71949097098     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. But DY-K, Lai C-L, Yuen M-F: Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14 (11): 1652-1656.
2. Di Bisceglie A M: Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (1): 34.
3. Makris BM, Garson CJA, Ring PW: Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993; 81:1898-1902.
4. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J: Prognostic significance of simulataneous measaurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 111-117. (Pubitemid 43129532)
5. Yoon SK, Lim NK, Ha SA, Park YG, Chio JY, Chung KW, Sun HS, Choi MJ, Chung J, Wands JR, Kim JW: The human hepatocellular carcinoma. Gene Res 2004; 64: 5434-5441.
6. Harn P, Tang ZY, Ye SL, Liu BB: Relationship between expression of α-fetoprotein messenger RNA and some clinical parameters of human hepatocellular carcinoma. World J. Gastroenterol 1999; 5:111-115.
7. Khien W, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, Satomura S: Clinical evaluation of lentil lectin - reactive alpha - fetoprotein L3 in histology - proven hepatocellular carcinoma. Int. J. Biol. Markers 2001; 16 (2): 105-111.
8. Kao CF, Chen SY, Chen JY, Lee YW: Modulation of p53 transcription regulatory activity and post -transcriptional modification by hepatitis C virus core protein. Oncogene 2004; 1: 12.
9. Ryan KM, Phillips AC, Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332-337. (Pubitemid 32429498)
10. Guan Y-S, He Q, La Zi: Roles of p53 in carcinogenesis, diagnosis and treatment of hepatocellular carcinoma. Journal of Cancer Molecules 2006; 2 (5): 191-197.
11. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA: Hepatitis B, aflatoxin B (1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Bio-markers Prev 2001; 10: 617-625.
12. Semela D, Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-880.
13. Yamaguchi R, Yano H, Nakashima O, et al: Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21: 152-160.
14. Hisai H, Kato J, Kobune M, et al: Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 2003; 9: 4852-4859. (Pubitemid 37323289)
15. Pang R, Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151-167. (Pubitemid 44485315)
16. Engvall E, Perlman P: Enzyme linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochem 1971; 8(9): 871-874.
17. Katiyar S, Dash BC, Thakur V, Guptan RC, Sarin SK, Das BC: p53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000; 88 (7): 1565-1573. (Pubitemid 30183141)
18. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum a- fetoprotein levels. Cancer 1989; 64:1700-1707
19. Nichols CR, Saxman S, Williams SD, Loehrer PJ, Miller ME, Wright C, et al: Primary mediastinal non-seminomatous germ cell tumors. A modern single institution experience. Cancer 1990; 65:1641-1646
20. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al: Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and Anti-HCV status. J Hepatol 2001; 34: 570-575
21. Johnson PJ, Williams R: Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987; 4:140-147
22. Raedle J, Oremek G, Truschnowitsch M, Lorenz M, Roth WK, Caspary WF, Zeuzem S: Clinical evaluation of auoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer 1998; 34 (8): 1198-1203. (Pubitemid 28342109)
23. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F: Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532.
24. Bergstrom S, Dreilich M, Wagenius G, Brattstrom D, Larsson A, Hesselius P, Bergqvist M: The presence of anti-p53 antibodies in sera from patients with esophageal carcinoma: correlation to treatment, tumor volume and survival. In Vivo 2004; 18: 615-620. (Pubitemid 39409638)
25. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C: Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004: 1070-1077. (Pubitemid 40053006)
26. Charuruks N, Tangkijvanich P, Voravud N, Chatsantikl R, Theamboonlers A, Poovorawan Y: Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol 2001; 36: 830-836.
27. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A: Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999; 79 (3-4): 604-610.
28. Tangkijvanich P, Janchai A, Charuruks N, Kullavanijaya P, Theamboonlers A, Hirsch P, Poovorawan Y: Clinical associations and prognostic significance of serum anti - p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pac J Allergy Immunol 2000; 18 (4): 237-243.
29. Gottschlich S, Hoffmann M, Maass J D, Gororgh T, Buhmann V, Hoffmann - Fazel A, Rudert H, Maune S: p53 autoantibodies as tumor markers in head and neck squamous cell cancer. Anticancer Res 2003; 23 (2): 913-915.
30. Ryder SD, Rizzi PM, Volkmann M, Metivier E, Pereira LM, Galle PR, Naoumov NV, Zentgraf H, Williams R: Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 1996; 49 (4): 295-299.
31. Bergquist J, Gobom J, Blomberg A, Roepstorff P, Ekman, R: Identification of nuclei associated proteins by 2D - gel electrophoresis and mass spectrometry. J. Neurosci. Methods 2001; 109 (1): 3-11. (Pubitemid 32727882)
32. Volkmann M, Muller M, Hoffmann WJ, Meyer M, Hagelstien J, Rath U, Kommerell B, Zentgraf H, Galle PR: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy ad independent of the alpha - fetoprotein status. Hepatology 1993; 18 (3): 559-565. (Pubitemid 23259954)
33. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, Shopland DR, Eyre HJ, Pechacek TF: Smoking - attributable cancer mortality lung cancer now the leading cause of death among smokers in the United State. Cancer Inst 1997; 83:1142-1148.
34. Raedle J, Oremek G, Roth W K, Cspary WF, Zeuzem S: Anti - p53 autoantibodies in hepatitis C virus infected patients. Anticancer Res 1997; 17 (4): 3079-3081.
35. Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H, Galle P R: Overexpression is frequent in European hepatocellular carcinoma and largely than of the codon 249 hot spot mutations. Oncogene 1994; 9: 195-204. (Pubitemid 24020950)
36. Soussi, T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60 (7): 1777-1788. (Pubitemid 30207629)
37. Watanabe J, Nishiyama H, Kawanishi H, Ito M, Kamoto T, Ogawa O: Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors. J Urol 2005; 174: 73-75. (Pubitemid 40825675)
38. Numa F, Umayahara KJ, Suehiro Y, Hirakawa H, Nawata S, Suminami Y, Oga A, Ito T, Sasaki K, Kato H: Serum anti-p53 antibodies in uterine and ovarian cancer: association with DNA sequence copy number abnormalities. Tumor Biol 2001; 22: 162-168. (Pubitemid 32245412)
39. Mocci F, Nettuno M: Plasma mutant-p53 protein and anti-p53 antibody as a marker: an experience in vinyl chloride workers in Italy. J Occup Environ Med 2006; 48: 148-164. (Pubitemid 43237947)
40. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785. (Pubitemid 34273266)
41. Yao DF, Wu XH, Zhu Y, et al: Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220-226. (Pubitemid 40790169)
42. Frachon S, Gouysse G, Dumortier J, et al: Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001; 34:850-857. (Pubitemid 32595184)
43. Nakashima T, Kojiro M: Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986; 6:259-266.
44. Brodsky SV, Mendelev N, Melamed M, Ramaswamy G: Vascular density and VEGF expression in hepatic lesions. J Gatrointestin liver Dis 2007; 16 (4): 373-377.
45. Yamaguchi R, Yano H, Nakashima Y, et al: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000; 7: 725-729.
46. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R: Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195. (Pubitemid 38569038)
47. Yamamoto A, Dhar DK, El-Assal ON, Igarashi M, Tabara H, Nagasue N: Thymidine Phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol 1998; 29:290-299. (Pubitemid 28352815)
48. Deli G, Jin CH, Mu R, et al: Immunobistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11:960-963. (Pubitemid 40347745)
49. Mathonnet M, Descottes B, Valleix D, Labrousse F, Denizot Y: VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2006; 12: 830-831. (Pubitemid 43380777)
50. Rosmorduc O, Wendum D, Galy B, Huez I, Prat H, de Saint-Maur PP, Poupon R: Expression of the angiogenic factors basic FGF and VEGF in human cirrhosis and hepatocellular carcinoma. Hepatology 1996; 24: 341.
51. El - Assal O N, Yamanoi A, Soda, Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554-1562.